Evaluation of Safety and Tolerability of Long-term TEV-50717 for Treatment of Tourette Syndrome

Study Title
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
Teva Identifier
TV50717-CNS-30047 | 2016-000630-22
ClinicalTrials.gov Identifier
NCT03567291
Study Status
Terminated
Trial Condition(s)
Tourette Syndrome
Interventions
Drug: TEV-50717 | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
6 Years to 17 Years
Trial Duration
May 25, 2018 - May 15, 2020
Phase
Phase 3

Study Type

Interventional